Sampson Kira, Sorenson Carlise, Adamala Katarzyna P
Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA.
Synth Biol (Oxf). 2024 Jan 27;9(1):ysae004. doi: 10.1093/synbio/ysae004. eCollection 2024.
Synthetic cells are a novel class of cell-like bioreactors, offering the potential for unique advancements in synthetic biology and biomedicine. To realize the potential of those technologies, synthetic cell-based drugs need to go through the drug approval pipeline. Here, we discussed several regulatory challenges, both unique to synthetic cells, as well as challenges typical for any new biomedical technology. Overcoming those difficulties could bring transformative therapies to the market and will create a path to the development and approval of cutting-edge synthetic biology therapies. .
合成细胞是一类新型的类细胞生物反应器,为合成生物学和生物医学的独特进展提供了潜力。为了实现这些技术的潜力,基于合成细胞的药物需要通过药物审批流程。在此,我们讨论了几个监管挑战,既有合成细胞所特有的,也有任何新生物医学技术常见的挑战。克服这些困难可能会将变革性疗法推向市场,并将为前沿合成生物学疗法的开发和审批开辟一条道路。